Bourguet W, Germain P, Gronemeyer H
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS/INSERM/ULP, BP 163, 67404 Illkirch Cedex, C.U. de Strasbourg, France.
Trends Pharmacol Sci. 2000 Oct;21(10):381-8. doi: 10.1016/s0165-6147(00)01548-0.
Nuclear receptors are members of a large family of ligand-inducible transcription factors that regulate gene programs underlying a plethora of (patho)physiological phenomena. The recent determination of the crystal structures of nuclear receptor ligand-binding domains has provided an extremely detailed insight into the intra- and intermolecular mechanisms that constitute the initial events of receptor activation and signal transduction. Here, a comprehensive mechanistic view of agonist and antagonist action will be presented. Furthermore, the novel class of partial agonists-antagonists will be described and the multiple challenges and novel perspectives for nuclear-receptor-based drug design will be discussed.
核受体是一大类配体诱导型转录因子的成员,它们调节众多(病理)生理现象背后的基因程序。最近对核受体配体结合域晶体结构的测定,为构成受体激活和信号转导初始事件的分子内和分子间机制提供了极其详细的见解。本文将介绍激动剂和拮抗剂作用的全面机制观点。此外,还将描述新型的部分激动剂 - 拮抗剂,并讨论基于核受体的药物设计面临的多重挑战和新观点。